Get started
Kyverna Therapeutics, Inc.Kyverna Therapeutics, Inc.Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

KYTX trade ideas

KYTX: Trendline Breakout Targets $4.86–$5.84 ZoneAfter months of consolidation at depressed levels, the setup finally resolved with conviction. The chart shows a clean break above long-standing trendline resistance (new support), after a bullish reversal off that $2.50 zone -- a level that’s now proven to be a meaningful pivot. July 11 marked the first close above $4 in quite some time, with above average volume confirming the move. I’ve mapped out a target zone between $4.86 and $5.84 -- technically achievable based on prior supply zones and recent momentum. This aligns with H.C. Wainwright’s $5 PT, which frankly still feels conservative given the pipeline and float dynamics. Chart speaks for itself. Let’s see how this plays out. Stay tuned!
NASDAQ:KYTX
by BluntForceOptions
KYTX: Healthy Retracement After Strong Move – Key Support LevelsChart update: We tagged resistance at $4.44 (R-1) before pulling back and closing right at S-1 support ($3.82). After the strong multi-day run from the $2.50 zone, this kind of retracement is normal... even healthy. If we see further downside, I’m watching $3.25 (S-2), which lines up well with the reclaimed trendline that should now serve as support. Still viewing this as digestion, not distribution. Setup’s intact, IMO. Stay tuned.
NASDAQ:KYTX
by BluntForceOptions
KYTX: Cup & Handle Breakout in Progress, Targeting R-4 ZoneChart update: KYTX broke above the neckline of the cup and handle pattern I flagged on Apr 24. I’ve updated the chart with short-term price targets at R-1: $2.52, R-2: $2.62, R-3: $2.71, and R-4: $2.91 -- which also aligns with the SMA 100, making that zone a key double resistance level. I’m particularly focused on the $2.71–$2.91 range, which looks well within reach. To be clear: if price can push through and hold above the R-4/SMA 100 confluence, there’s room for meaningful extension. If it bases in that zone, a move well above $3 is firmly on the table. The setup remains technically intact, and the stock is fundamentally mispriced, IMO. There's plenty of upside here, y'all, as this one continues to build. As always, do your own DD. Giddy up!
NASDAQ:KYTXLong
by BluntForceOptions
KYTX: Cup & Handle Forming on a Deep Value BackdropTechnically, KYTX is setting up with a classic cup and handle. The cup has formed, the handle is in development, and price is tightening just beneath the breakout level. A clean move through resistance could trigger a strong upside extension -- the structure is solid. Now for the backstory: At $2.14, NASDAQ:KYTX is trading at a level that’s hard to justify by any rational measure. The company holds approx. $285.98M in cash against just $8.24M in debt, resulting in a net cash position of $277.74M, or $6.43 per share. Meanwhile, the market cap sits at just $90.98M, giving the stock a negative EV of -$186.98M. That’s not just undervalued -- it’s structurally mispriced, IMO. Factor in institutional ownership from heavyweights like Gilead Sciences (9.56%), Bain Capital Life Sciences (7.8%), Novo Holdings (4.28%), Westlake Village BioPartners (10.5%), and Vida Ventures (10.47%), and it's clear that some of the smartest money in biotech is backing this name. The dislocation between price and fundamentals here is, frankly, laughable. At some point, the market will have to reconcile that. As always, do your own DD. I'm long and bullish. Stay tuned!
NASDAQ:KYTXLong
by BluntForceOptions